Transforming growth factor β--at the centre of systemic sclerosis.
about
Current perspectives on the immunopathogenesis of systemic sclerosisEndothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic DiseasesVascular Remodelling and Mesenchymal Transition in Systemic SclerosisInflammation as a Keystone of Bone Marrow Stroma Alterations in Primary MyelofibrosisAnti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosisA Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related FibrosisPathogenesis of Systemic Sclerosis.Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis.Wenyang Huazhuo Tongluo formula, a Chinese herbal decoction, improves skin fibrosis by promoting apoptosis and inhibiting proliferation through down-regulation of survivin and cyclin D1 in systemic sclerosis.Targeting c-fms kinase attenuates chronic aristolochic acid nephropathy in miceBosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study.Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production.Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis.Promising pharmacological directions in the world of lysophosphatidic Acid signaling.Recent advances in understanding contextual TGFβ signalingBiomarkers in systemic sclerosis: Their potential to predict clinical courses.Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?Recent advances in managing systemic sclerosis.Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.Interleukin-9 and T helper type 9 cells in rheumatic diseases.Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis.Morphea and Eosinophilic Fasciitis: An Update.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration.PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosisIncreased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.The fibrotic tumor stroma.TGFB1 is secreted through an unconventional pathway dependent on the autophagic machinery and cytoskeletal regulators.Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor.Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.Periostin in the pathogenesis of skin diseases.Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis.The role of long non-coding RNAs in rheumatic diseases.Transforming growth factor-β signaling in systemic sclerosis.
P2860
Q26741264-14A6C51F-67C6-4857-AE26-FDCB48BB5566Q26748338-8236DB50-F75A-4574-86AE-AA45C5626D76Q26749091-6D2699BF-6FF6-4970-9DD3-25FD9C1049F1Q26774212-7DE3CFA9-867F-4CF0-9058-16520683E484Q33795658-6DEEF769-BAF0-48D4-99FE-E61DC9999C24Q35587696-C82D6444-A570-4941-AFB5-3FF963968B62Q35693212-434E5EE1-AD86-4955-A57F-DA7BBBE98FCEQ35710188-6A469BE1-7576-4F72-B546-EE45AD3121FCQ35929260-DBAADD54-B1BB-48CF-B793-6DD16B37891FQ36998106-E6B2E69E-949F-4831-966F-E96D83C966DDQ37316247-C6563C1A-B951-4055-8AA2-44797F9A5A8FQ37443706-54CD679C-CAFA-4014-B83D-CD6716BF8B4DQ37471585-6C6B22F0-7489-4009-8FED-3A72914D9460Q37514840-250F694A-3F62-4ACC-8F26-FF5BF513A5A2Q37643874-BE2B6151-492D-41A1-8230-71F47EA52953Q38320338-C9A16C2F-CEF1-4943-9AB8-5D80E8D5F461Q38666840-069047CF-D558-47D7-B6BD-9CA8C4666FB1Q38701985-8BDC8B7A-8B0C-4917-867A-C782499ECA3FQ38710580-4B31F4F3-9CAB-4F97-B6BA-D7D7DA20A318Q38759138-4F16E13B-59AF-4171-A5D9-D0FAFDD70BEDQ38824987-3E5E29F3-22EB-4520-ADF7-5801A9774A8AQ38829766-92F32B4F-7C3D-4934-95C4-764ADA51B757Q38873978-6B04D7E7-73E6-49ED-A72C-55CE76F3862AQ38902145-6FA09781-6156-4159-916D-96A94D788297Q38956376-B373E73D-8445-4080-B77C-639196708C72Q39233347-83B5B650-9AB5-4A6B-9E94-776BB9D37DFEQ41630154-61D434BF-F7E1-47B4-A94A-2A92570A1E2BQ41980258-041EA1F1-7744-4208-B541-DFB51A0532C7Q42090906-7AD05BD8-3E31-4B84-83F9-A2DC703AA650Q42652598-36812A5D-1E1D-43C7-83D6-BFD4D6FE850FQ43240966-A5ABE89F-0776-45CA-BE17-549B22551F8FQ47133379-2ED9AB5B-0648-40DF-BD6D-22C3568D2AEAQ47205727-FE190A48-2A6A-492C-80AD-B45AABA31ED0Q47214972-754BE1FC-3974-4BA7-A797-FBF24B31F31BQ47280656-2020A955-57B1-4A19-956A-7287EBF4F3C4Q47718418-289DF58B-EA25-40F8-8603-04012824D4FDQ47792957-75B6B9E7-E9E4-4CA5-BD49-47228E645267Q48067747-83462271-D5EC-4C86-B5F7-6A914393C523Q49596604-54BB9D31-985E-4695-A474-CF39C37ADB55Q49895124-DD2E9A39-5DB6-42F1-B1CD-DDFAEAF2F91A
P2860
Transforming growth factor β--at the centre of systemic sclerosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Transforming growth factor β--at the centre of systemic sclerosis.
@en
type
label
Transforming growth factor β--at the centre of systemic sclerosis.
@en
prefLabel
Transforming growth factor β--at the centre of systemic sclerosis.
@en
P2860
P356
P1476
Transforming growth factor β--at the centre of systemic sclerosis.
@en
P2093
Robert Lafyatis
P2860
P2888
P304
P356
10.1038/NRRHEUM.2014.137
P407
P577
2014-08-19T00:00:00Z
P6179
1029522095